Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
Alzheimer's & Dementia · 2024-11 · 20 (11) · 8216-8224
DOI: 10.1002/alz.14184 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Alzheimer's & Dementia, 2024-10. Verfasst von Michelle M Mielke und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers. Die Arbeit wurde bisher 125-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Blood‐based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease‐modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer's Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, USA.
- Atrium Health, Charlotte, North Carolina, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.
- War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, California, USA.
- ALZpath, Carlsbad, California, USA.
- Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA.
ORCID-Profile: Michelle M Mielke, Emily Scholler
Förderung
- NIA NIH HHS
Zitieren
APA
Mielke, M. M., Anderson, M., Ashford, J. W., Jeromin, A., Lin, P. J., Rosen, A., Tyrone, J., Vandevrede, L., Willis, D. R., Hansson, O., Khachaturian, A. S., Schindler, S. E., Weiss, J., Batrla, R., Bozeat, S., Dwyer, J. R., Holzapfel, D., Jones, D. R., Murray, J. F., …, & Udeh-Momoh, C. T. (2024). Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease. Alzheimer's & Dementia, 20(11), 8216-8224. https://doi.org/10.1002/alz.14184
Vancouver
Mielke MM, Anderson M, Ashford JW, Jeromin A, Lin PJ, Rosen A, et al. Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease. Alzheimer's & Dementia. 2024;20(11):8216-8224. doi:10.1002/alz.14184
BibTeX
@article{Mielke2024,
author = {Mielke, Michelle M and Anderson, Matthew and Ashford, J Wesson and Jeromin, Andreas and Lin, Pei-Jung and Rosen, Allyson and Tyrone, Jamie and Vandevrede, Lawren and Willis, Deanna R and Hansson, Oskar and Khachaturian, Ara S and Schindler, Suzanne E and Weiss, Joan and Batrla, Richard and Bozeat, Sasha and Dwyer, John R and Holzapfel, Drew and Jones, Daryl Rhys and Murray, James F and Partrick, Katherine A and Scholler, Emily and Vradenburg, George and Young, Dylan and Braunstein, Joel B and Burnham, Samantha C and de Oliveira, Fabricio Ferreira and Hu, Yan Helen and Mattke, Soeren and Merali, Zul and Monane, Mark and Sabbagh, Marwan Noel and Shobin, Eli and Weiner, Michael and Udeh-Momoh, Chinedu T},
title = {Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease},
journal = {Alzheimer's & Dementia},
year = {2024},
volume = {20},
number = {11},
pages = {8216--8224},
doi = {10.1002/alz.14184}
}
EUVIMED